Media

News

Octarine receives funding to develop biosynthetic platform for cannabinoid and psilocybin derivatives

Octarine Bio IVS (“Octarine” or the “Company”), a synthetic biology company developing functionally superior cannabinoid and psilocybin derivatives using microbial…

Read more

Insights

Media contact details

Alexandre OUIMET STORRS

Nicola BROUGHTON